## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 2.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. GE HealthCare Technologies Inc. $GEHC Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251224T141133 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC decreased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 10.8% during the third quarter, while other major institutions like Vanguard, Dodge & Cox, State Street, Geode, and Norges Bank increased their holdings. GE HealthCare reported strong quarterly results, beating EPS and revenue estimates, and announced a modest quarterly dividend. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $87.09.

**2. Is Boston Scientific (BSX) One of the Best Healthcare AI Stocks to Buy Now?**
- Source: Finviz | 20251223T010913 | Neutral | Relevance: 64%
- TD Cowen has reaffirmed a Buy rating on Boston Scientific (BSX), naming it their "Best Idea for 2026" due to its strong growth story in the medical devices sector. The firm expects over 10% organic sales growth annually and double-digit EPS growth, driven by key products like Farapulse and Watchman. Boston Scientific also leverages AI in its medical devices to enhance imaging, predictive analytics, and remote monitoring.

**3. Morgan Stanley Raises iRhythm (IRTC) PT on MedTech Recovery Outlook**
- Source: Yahoo Finance UK | 20251222T145613 | Somewhat-Bullish | Relevance: 61%
- Morgan Stanley increased its price target for iRhythm Technologies (IRTC) from $195 to $205, maintaining an Overweight rating, based on a positive outlook for the MedTech industry. The industry is expected to benefit from new product cycles, supportive hospital spending, and attractive valuations. Additionally, new data shows iRhythm's Zio long-term continuous ECG monitoring system performs consistently across diverse patient populations.

**4. Seilern Investment Management Ltd Sells 183,101 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251222T110830 | Neutral | Relevance: 60%
- Seilern Investment Management Ltd reduced its stake in Edwards Lifesciences Corporation by 14.8%, selling 183,101 shares and now holding 1,055,774 shares valued at approximately $82.1 million. The article notes that insider selling has occurred this quarter, while institutional investors own a significant portion of the stock. Analyst sentiment remains bullish-to-neutral with a "Moderate Buy" consensus rating and a $93.95 target price, following Edwards Lifesciences' recent positive quarterly results and FY2025 EPS guidance.

**5. Guardant Health (GH) Leads Healthcare Stocks with 226.48% YTD Ga**
- Source: GuruFocus | 20251223T050954 | Neutral | Relevance: 59%
- Guardant Health (GH) has become the top performer among healthcare service stocks with a 226.48% year-to-date increase, driven by its leadership in liquid-based cancer diagnostics and FDA-approved products. Despite its strong stock performance and market capitalization, the company faces financial challenges, including negative operating margins, high debt, and significant stock volatility, alongside insider selling. Analysts maintain a positive recommendation, but the valuation and risk assessment suggest a mixed financial outlook.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.48 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.1B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.48 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.2% to -1.7% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.66% (CS: 33) | Neutral |
| RSI_14 | 57.7 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.066x | Above |
| vs SMA200 | 1.120x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.39
- **Stop Loss:** $79.71 (4.4% risk)
- **Target:** $87.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 326
- **Position Value:** $27,185.14
- **Portfolio %:** 27.19%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*